Program
Decitabine
Also written as “decitabine”, “decitabine (5-aza-2'deoxycytidine)” and “IV Decitabine”.
Its studies are mostly in Myelodysplastic Syndromes · Leukemia, Myeloid, Acute · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Lymphoma, T-Cell, Peripheral · Leukemia, Myeloid, led by 9 companies.
Drug pageDecitabine: every studyMany companies study it; this page follows only the 28 they lead. All 277 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 90 open or running | phase 4since Nov 5, 2009 | Nov 28, 2005 | none ahead |
| Otsukaits history only | 82 open or running | phase 3since Aug 8, 2002 | Jul 19, 2002 | none ahead |
| EpiDestinyits history only | 30 open or running | phase 1since Jan 31, 2019 | Jan 31, 2019 | none ahead |
| Johnson & Johnsonits history only | 30 open or running | phase 2since Aug 29, 2008 | Aug 29, 2008 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since May 3, 2019 | May 3, 2019 | none ahead |
| Dong Wha Pharmaceutical | 10 open or running | phase 1since Sep 8, 2017 | Sep 8, 2017 | none ahead |
| Imunopharm Technologyits history only | 10 open or running | phase 1since May 14, 2018 | May 14, 2018 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 4since Dec 9, 2013 | Dec 9, 2013 | none ahead |
| Treebough Therapiesits history only | 11 open or running | phase 1since May 20, 2025 | May 20, 2025 | Dec 30, 2026phase 1 · NCT07006025 |
Also a collaborator on its studies: dsm-firmenich.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dong Wha Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2017First study: phase 1 study in Advanced Breast CancerFirst studyNCT03282825 · 18 enrolled · Korea, Republic of
TargetBeta
“DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor; DNA inhibitor”ChEMBL 37, by rule
Studies
The one study Dong Wha Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03282825Advanced Breast Cancer · Korea, Republic of | 1 | UNKNOWN | Feb 2018 | 18 |
How it is read
Names in the registry
- “Decitabine”, 14 entries
- “decitabine”, 8 entries
- “decitabine (5-aza-2'deoxycytidine)”, 4 entries
- “IV Decitabine”, 1 entry
- “Decitabine + Cedazuridine”, 1 entry
Conditions, from the studies’ own filings
- Myelodysplastic Syndromes, 13 studies
- Leukemia, Myeloid, Acute, 7 studies
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 2 studies
- Lymphoma, T-Cell, Peripheral, 1 study
- Leukemia, Myeloid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.